Jazz Pharmaceuticals JAZZ Inventory-related accruals
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:AccruedInventoryRelatedLiabilitiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's inventory-related accruals.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's inventory-related accruals?
- Jazz Pharmaceuticals (JAZZ) reported inventory-related accruals of $57.3M in Q1 2026.
- How has Jazz Pharmaceuticals's inventory-related accruals changed year-over-year?
- Jazz Pharmaceuticals's inventory-related accruals increased by 109.2% year-over-year, from $27.4M to $57.3M.
- What is the long-term trend for Jazz Pharmaceuticals's inventory-related accruals?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's inventory-related accruals has grown at a 58.3% compound annual growth rate (CAGR), from $8.57M to $34M.